<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A non-total body irradiation-containing preparative regimen was studied in young children (&lt;4 years old) undergoing unrelated donor cord blood transplantation as part of the Cord Blood Transplantation trial for the treatment of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 14), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n = 13), undifferentiated <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 1), juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 2), and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (n = 2) </plain></SENT>
<SENT sid="1" pm="."><plain>Donor/recipient HLA matching based on low-/intermediate-resolution molecular typing for HLA-A and -B and high-resolution HLA-DRB1 typing was 5/6 or 6/6 (n = 21) or 4/6 (n = 11) </plain></SENT>
<SENT sid="2" pm="."><plain>The preparative therapy consisted of <z:chebi fb="0" ids="28901">busulfan</z:chebi>, melphalan, and antithymocyte globulin, with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis </plain></SENT>
<SENT sid="3" pm="."><plain>The median age was 1.6 years (range, 0.5-3.9 years), and the median weight was 10.5 kg (range, 5.8-19.5 kg) </plain></SENT>
<SENT sid="4" pm="."><plain>Cord blood grafts contained a median of 10.7 x 10 7 nucleated cells per kilogram (range, 4.6-29.2) and 2.6 x 10(5) CD34+ cells per kilogram (range, 0.7-8.3) </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative incidence (CINC) of neutrophil recovery (absolute neutrophil count &gt;500/microL) at day 42 was 0.59 (95% confidence interval [CI], 0.44-0.78) at a median of 31 days (range, 23-55 days) </plain></SENT>
<SENT sid="6" pm="."><plain>The CINC and Kaplan-Meier estimates of platelet engraftment at day 180 were 0.53 (95% CI, 0.34-0.69) and 0.82 (95% CI, 0.61-1.00), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CINC estimates of grade III/IV <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD at day 100 and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD at 1 year were 0.25 (95% CI, 0.09-0.41) and 0.26 (95% CI, 0.09-0.44), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The CINC estimate of relapse was 0.31 (95% CI, 0.16-0.47) at 2 years </plain></SENT>
<SENT sid="9" pm="."><plain>With a median follow-up of 27.8 months (range, 23.4-46.7 months), the probability of survival at 1 year was 0.47 (95% CI, 0.30-0.64) </plain></SENT>
<SENT sid="10" pm="."><plain>A preparative regimen containing a <z:chebi fb="0" ids="28901">busulfan</z:chebi>/melphalan/antithymocyte globulin preparative regimen is well tolerated in the setting of unrelated donor cord blood transplantation for childhood <z:hpo ids='HP_0001909'>leukemia</z:hpo> and can serve as a platform preparative regimen for intensifying host immunosuppression and antileukemic therapy to allow for improved engraftment and improved relapse-free survival </plain></SENT>
</text></document>